市場調查報告書
商品編碼
1413824
病理學人工智慧市場:按組件、神經網路、應用程式和最終用戶分類 - 2024-2030 年全球預測AI in Pathology Market by Component (Hardware, Software), Neural Network (Convolutional neural networks (CNNs), Generative adversarial networks (GANs), Recurrent neural networks (RNNs)), Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
病理學人工智慧市場規模預估2023年為2,901萬美元,預估2024年將達3,336萬美元,2030年將達7,875萬美元,複合年成長率為15.33%。
病理學人工智慧的全球市場
主要市場統計 | |
---|---|
基準年[2023] | 2901萬美元 |
預測年份 [2024] | 3336萬美元 |
預測年份 [2030] | 7875萬美元 |
複合年成長率(%) | 15.33% |
病理學中的人工智慧 (AI) 透過整合先進的計算技術、機器學習演算法和影像分析工具來自動化診斷過程的各個方面,從而提高病理診斷的速度、準確性和效率。準確快速診斷的新興市場的開拓、需要及時診斷的癌症等慢性病盛行率的上升以及數位病理基礎設施的持續發展都有力地促進了市場的成長。此外,政府也持續投資研發活動和支持性舉措,旨在加速醫療數位化。此外,對於許多醫療機構來說,開發和整合基於人工智慧的病理學解決方案可能成本高昂。此外,使用雲端基礎的解決方案共用患者資料會引發對資料外洩和未授權存取敏感資訊的擔憂。除此之外,機器學習技術和人工智慧能力的快速進步正在為市場成長創造潛在機會。此外,可以利用區塊鏈等新技術來確保患者資料的安全儲存和傳輸。
區域洞察
在美洲,人工智慧主導的病理解決方案正在進行大量投資,以推動數位診斷。食品藥物管理局也開始批准基於人工智慧的醫療設備,這表明這些技術正在獲得認可。歐盟委員會的計劃為專注於健康和護理數位轉型的計劃提供了大量資金。改善歐盟地區的醫療基礎設施為基於人工智慧的病理解決方案提供了獨特的機會。在亞太地區,領先的公司正在大力投資數位診斷。政府措施也支持該領域的研究和開發,產生了大量專利和研究出版物。此外,亞太地區新興經濟體醫療保健基礎設施的發展正在推動數位醫療保健解決方案的採用。
FPNV定位矩陣
FPNV定位矩陣對於評估病理市場的AI至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一個綜合工具,可以對病理學市場人工智慧供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴考察,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1-市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2-市場開拓:我們深入研究利潤豐厚的新興市場,並分析它們在成熟細分市場中的滲透率。
3- 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4-競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5- 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1-病理學AI市場的市場規模和預測是多少?
2-在病理學市場的人工智慧預測期內,有哪些產品、細分市場、應用程式和領域需要考慮投資?
3-病理學AI市場的技術趨勢和法律規範是什麼?
4-病理學市場AI主要廠商的市場佔有率是多少?
5-進入病理AI市場有哪些合適的型態與策略手段?
[183 Pages Report] The AI in Pathology Market size was estimated at USD 29.01 million in 2023 and expected to reach USD 33.36 million in 2024, at a CAGR 15.33% to reach USD 78.75 million by 2030.
Global AI in Pathology Market
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 29.01 million |
Estimated Year [2024] | USD 33.36 million |
Forecast Year [2030] | USD 78.75 million |
CAGR (%) | 15.33% |
Artificial intelligence (AI) in pathology integrates advanced computational techniques, machine learning algorithms, and image analysis tools to improve pathological diagnoses' speed, accuracy, and efficiency by automating various aspects of the diagnostic process. Increasing demand for accurate and quick diagnostics, the rising chronic diseases prevalence such as cancer that require timely diagnosis, and continuous developments in digital pathology infrastructure strongly contribute to the growth of the market. In addition, ongoing investments in research and development activities and supportive government initiatives aimed at promoting healthcare digitization. Furthermore, the development and integration of AI-based solutions in pathology can be an expensive affair for many healthcare organizations. Also, the usage of cloud-based solutions for sharing patient data raises concerns about data breaches and unauthorized access to sensitive information. Apart from this, rapid advancements in machine learning techniques & artificial intelligence capabilities create a potential opportunity for market growth. Additionally, emerging technologies such as blockchain can be leveraged to ensure secure storage and transfer of patient data.
Regional Insights
In the Americas, significant investments have been made in AI-driven pathology solutions to advance digital diagnostics. The Food and Drug Administration has also started approving AI-based medical devices, demonstrating an increasing acceptance of such technologies. The European Commission's program has provided significant funding for projects focusing on digital transformation in health and care. Improved healthcare infrastructure in the EU region presents a unique opportunity for AI-based pathology solutions. In the APAC region, major players have made significant investments in digital diagnostics. Government initiatives have also supported R&D in this sector, leading to numerous patents and research publications. Also, the development of healthcare infrastructure in the developing economies of the APAC region endorses the adoption of digital healthcare solutions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the AI in Pathology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the AI in Pathology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the AI in Pathology Market, highlighting leading vendors and their innovative profiles. These include aetherAI, Aiforia Technologies Oyj, Akoya Biosciences, Inc., Deep Bio, Inc., Evident Corporation, F. Hoffmann-La Roche Ltd., Ibex Medical Analytics Ltd., Indica Labs, Inc., Inspirata, Inc., LUMEA, Inc., MindPeak GmbH, Nucleai Inc., OptraSCAN Inc., Paige.AI, Inc., PathAI, Inc., Proscia Inc., Techcyte, Inc., Tempus Labs, Inc., Tribun Health, Visikol, Inc. by CELLINK, and Visiopharm A/S.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the AI in Pathology Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the AI in Pathology Market?
3. What are the technology trends and regulatory frameworks in the AI in Pathology Market?
4. What is the market share of the leading vendors in the AI in Pathology Market?
5. Which modes and strategic moves are suitable for entering the AI in Pathology Market?